T. Rowe Price Amends 13G: Holds 5.97M KMTS Shares

T. Rowe Price Associates filed an amendment to Schedule 13G reporting beneficial ownership of 5,968,664 shares of Kestra Medical Technologies common stock, representing 10.2% of the class.

Rhea-AI Filing Summary

T. Rowe Price Associates filed an amendment to Schedule 13G reporting beneficial ownership of 5,968,664 shares of Kestra Medical Technologies common stock, representing 10.2% of the class. The filing lists sole voting power of 5,966,639 shares and sole dispositive power of 5,968,664 shares. The amendment is signed by Ellen York, Vice President, dated 04/08/2026.

Insights

Institutional Ownership Analyst

Large passive stake disclosed by T. Rowe Price; filing updates prior holdings.

The Schedule 13G/A amendment reports a 5,968,664-share position, equal to 10.2% of Kestra Medical Technologies' common stock. The filing specifies sole voting and dispositive power counts, which clarify the firm's control metrics in public records.

Because 13G filings are typically passive-investor disclosures, the filing signals significant institutional ownership but does not indicate active control actions; subsequent filings would show any change in intent or voting plans.

Compliance & Regulatory Specialist

Amendment documents beneficial ownership details and includes a formal disclaimer.

The amendment includes a declaration denying beneficial ownership in part, a common legal precaution used in filings to clarify the filer’s interpretation of ownership roles. The signature block shows the filing was executed by a Vice President on 04/08/2026.

Regulatory watchers will treat this as an updated disclosure of position size and voting/dispositive powers; no transaction direction or intent change is stated in the excerpt.

Key Figures

Beneficial ownership: 5,968,664 shares Percent of class: 10.2% Sole voting power: 5,966,639 shares +4 more

7 metrics

Beneficial ownership 5,968,664 shares Amount beneficially owned as reported in Item 4

Percent of class 10.2% Percent of common stock reported in Item 4

Sole voting power 5,966,639 shares Number with sole power to vote (Item 4(c)(i))

Sole dispositive power 5,968,664 shares Number with sole power to dispose (Item 4(c)(iii))

CUSIP G52441105 CUSIP shown on the filing cover

Signature date 04/08/2026 Date signed by Ellen York, Vice President

Filing header date 03/31/2026 Date shown near the filing header

Key Terms

Schedule 13G/A, beneficial ownership, sole dispositive power, sole voting power

4 terms

Schedule 13G/A regulatory

"Amendment No. 1 ) KESTRA MEDICAL TECHNOLOGIES COMMON STOCK"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficial ownership regulatory

"Item 4. | Ownership (a) | Amount beneficially owned: 5968664"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

sole dispositive power regulatory

"(iii) Sole power to dispose or to direct the disposition of: 5968664"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

sole voting power regulatory

"(i) Sole power to vote or to direct the vote: 5966639"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does T. Rowe Price report in KMTS?

T. Rowe Price reports beneficial ownership of 5,968,664 shares, representing 10.2% of Kestra Medical Technologies common stock. The filing lists sole voting power of 5,966,639 and sole dispositive power of 5,968,664 shares.

Is this a purchase or sale reported in the Schedule 13G/A for KMTS?

The amendment discloses position size, not a transaction, and does not state a purchase or sale. Schedule 13G/A updates ownership metrics; it does not itself indicate trading activity or change in investment intent.

When was the Schedule 13G/A amendment signed for KMTS?

The amendment is signed by Ellen York, Vice President, dated 04/08/2026. The filing header shows a date of 03/31/2026; the signature block provides the execution date for the amendment.

What voting and dispositive powers does T. Rowe Price hold for KMTS?

The filing shows sole voting power of 5,966,639 shares and sole dispositive power of 5,968,664 shares. No shared voting or dispositive powers are reported in the provided excerpt.

Does the filing indicate T. Rowe Price controls Kestra Medical Technologies?

The filing reports a 10.2% stake and specific voting/dispositive counts, but it does not state control or a change in intent; Schedule 13G/A disclosures alone do not imply corporate control actions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/08/2026 - 03:25 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

KESTRA MEDICAL TECHNOLOGIES

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

G52441105

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): G52441105

1

Names of Reporting Persons

T. Rowe Price Associates, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,966,639.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,968,664.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,968,664.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

10.2 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: KESTRA MEDICAL TECHNOLOGIES
(b)	Address of issuer's principal executive offices: 3933 LAKE WASHINGTON BLVD NE, SUITE 200, KIRKLAND, WA, 98033
Item 2.
(a)	Name of person filing: T. Rowe Price Associates, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.:
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5968664
(b)	Percent of class: 10.2 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 5966639
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 5968664
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Associates, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	04/08/2026